Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

leuprolide acetate sustained-release microspheres PT105

A sustained-release (SR) injectable microsphere formulation composed of the acetate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In females, prolonged administration results in a decrease in estradiol production and suppression of ovarian function. Leuprolide also reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.
Synonym:leuprorelin acetate sustained-release microspheres PT105
Code name:PT 105
PT-105
PT105
Search NCI's Drug Dictionary